ASX:ALT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Analytica Limited designs, develops, and supplies medical devices in Australia, the United Kingdom, and the United States. More Details


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Analytica's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-33.3%

ALT

-0.5%

AU Medical Equipment

-0.8%

AU Market


1 Year Return

-33.3%

ALT

-1.4%

AU Medical Equipment

-12.4%

AU Market

Return vs Industry: ALT underperformed the Australian Medical Equipment industry which returned -1.4% over the past year.

Return vs Market: ALT underperformed the Australian Market which returned -12.4% over the past year.


Shareholder returns

ALTIndustryMarket
7 Day-33.3%-0.5%-0.8%
30 Day-20.0%-5.7%-3.8%
90 Day0%1.5%0.3%
1 Year-33.3%-33.3%-0.2%-1.4%-9.2%-12.4%
3 Year-50.0%-50.0%30.5%24.6%16.4%1.5%
5 Year-66.7%-66.7%95.5%81.6%41.7%12.0%

Price Volatility Vs. Market

How volatile is Analytica's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Analytica undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Analytica is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Analytica has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of ALT's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Analytica regulatory filings.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Analytica forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Analytica has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Analytica performed over the past 5 years?

26.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALT is currently unprofitable.

Growing Profit Margin: ALT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALT is unprofitable, but has reduced losses over the past 5 years at a rate of 26.1% per year.

Accelerating Growth: Unable to compare ALT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (37.2%).


Return on Equity

High ROE: ALT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Analytica's financial position?


Financial Position Analysis

Short Term Liabilities: ALT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ALT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ALT has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ALT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ALT has less than a year of cash runway if free cash flow continues to grow at historical rates of 19.5% each year.


Next Steps

Dividend

What is Analytica current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.9yrs

Average board tenure


CEO

Geoff Daly

6.58yrs

Tenure

AU$282,875

Compensation

Mr. Geoff Daly, BE (Hons, Mech, UQ), MBA (Exec, AGSM), MIEAust CPEng (Mech, Biomed), MAICD has been the Chief Executive Officer of Analytica Ltd. since February 12, 2014. Mr. Daly served as the Chief Opera ...


CEO Compensation Analysis

Compensation vs Market: Geoff's total compensation ($USD203.84K) is about average for companies of similar size in the Australian market ($USD276.97K).

Compensation vs Earnings: Geoff's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Michael Monsour
Executive Chairman16.25yrsAU$82.13k25.01%
A$ 1.8m
Ross Mangelsdorf
CFO & Executive Director11.92yrsAU$192.72k3.17%
A$ 222.9k
Peter Corr
Non-Executive Director3.33yrsAU$54.75kno data

11.9yrs

Average Tenure

Experienced Board: ALT's board of directors are seasoned and experienced ( 11.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Analytica Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Analytica Limited
  • Ticker: ALT
  • Exchange: ASX
  • Founded: 1985
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$7.039m
  • Shares outstanding: 3.52b
  • Website: https://www.analyticamedical.com

Number of Employees


Location

  • Analytica Limited
  • 320 Adelaide Street
  • Brisbane
  • Queensland
  • 4000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALTASX (Australian Securities Exchange)YesOrdinary SharesAUAUDOct 2000
ALTCHIA (Chi-X Australia)YesOrdinary SharesAUAUDOct 2000

Biography

Analytica Limited designs, develops, and supplies medical devices in Australia, the United Kingdom, and the United States. The company’s lead product is PeriCoach system, an e-health treatment system for w ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/22 19:04
End of Day Share Price2020/09/22 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.